close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Santhera Pharmaceuticals Holding AG

< Previous 1 2 Next >
News headline image
Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Publishes Agenda for its Annual General Meeting
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Announces Positive AIFA Board Decision on Reimbursement of AGAMREE® (vamorolone) in Italy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Full Year 2025 Trading Update
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Receives Positive CHMP Opinion to Expand AGAMREE® (vamorolone) Use in Pediatric DMD Patients Aged Two and Older in the EU
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Appoints Orlando Oliveira as Chief Executive Officer
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Appoints Marc Clausse as Chief Commercial Officer to Lead Next Phase of Growth
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
AGAMREE® (vamorolone) Data Presented at MDA 2026 Confirm Comparable Long-Term Effectiveness for up to 8 Years of Treatment, with Clinically Meaningful Safety Advantages in Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Announces Proposed Inclusion and Reimbursement of AGAMREE® (Vamorolone) within Spain’s National Health System for the Treatment of Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Appoints Stifel as Corporate Finance Advisor
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Receives Swissmedic Approval of AGAMREE® (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Closes USD 13 Million Royalty Monetization Agreement
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Five-year data of AGAMREE® (vamorolone) in patients with DMD show improved safety profile with comparable effectiveness to standard of care corticosteroids
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Secures Agreement with Biomedica for the Distribution of AGAMREE® (Vamorolone) in Russia
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Announces Approval in Canada for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Provides Update on Convertible Bond Issued on 23 September 2025
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Announces Half Year 2025 Financial Results and Provides Corporate Update
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Secures CHF 20 Million Growth Funding to Accelerate Global AGAMREE® Rollout
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera extends Highbridge convertible bond to 30th September 2025
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Secures Agreement with GEN for the Distribution of AGAMREE® (Vamorolone) in Türkiye
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Full Year Results for the Year Ended 31 December 2024
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera Publishes Agenda for its Annual General Meeting
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera shares updates on commercial rollout of AGAMREE®
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
News headline image
Santhera proposes Dr. Melanie Rolli as new member of Board of Directors
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today